Exogenus Therapeutics
  • About us
    • Our Story
    • Team
    • Partners
    • Funding
      • EXCELLence
      • ExoTalent
      • Exolung
      • Texad
      • Exowound
      • Hexkin
      • Investors
  • Collaborative R&D
  • Technology
    • Umbilical Cord Blood
    • Extracellular Vesicles
    • Pipeline
    • IP & Publications
  • News
  • Careers
  • Contacts
Select Page
Joana Simões Correia is an invited  speaker  at the 3rd  Exosome  Based Therapeutic Development Summit

Joana Simões Correia is an invited speaker at the 3rd Exosome Based Therapeutic Development Summit

by admin | Nov 15, 2021 | News

Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 3rd Exosome Based Therapeutic Development Summit, taking place virtually on November 17th and 18th, as part of a panel discussion about “Comparing Engineered & Naturally...
Exogenus Therapeutics joins the massivEVs workshop to share insights about Exo-101’s production process and composition

Exogenus Therapeutics joins the massivEVs workshop to share insights about Exo-101’s production process and composition

by admin | Oct 28, 2021 | News

Our team member Carla Pereira will be attending the massivEVs workshop, organized by ISEV, with a poster titled “Manufacturing and characterization of extracellular vesicles from umbilical cord mononuclearcells for future clinical use”. She will be sharing published...
Exogenus Therapeutics receives 1st Place in the category of BioTech at the 2021 Go Global Awards

Exogenus Therapeutics receives 1st Place in the category of BioTech at the 2021 Go Global Awards

by admin | Oct 15, 2021 | News

Exogenus Therapeutics was announced as 1st Place in the category of BioTech on the 14th October 2021, at the International Trade Council’s Annual Go Global Awards Ceremony. Founded in 2015, Exogenus Therapeutics is an early-stage R&D biotech company,...
Exogenus Therapeutics strengthens IP portfolio with patent granted in Japan

Exogenus Therapeutics strengthens IP portfolio with patent granted in Japan

by admin | Oct 1, 2021 | News

Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in Japan. The patent describes the use of exosomes naturally secreted by umbilical cord blood mononuclear...
New study highlights Exo-101’s potential for inflammatory skin diseases

New study highlights Exo-101’s potential for inflammatory skin diseases

by admin | Sep 10, 2021 | News

A recent study published in the Journal of Molecular Sciences illustrates how Exo-101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo-101 as an adjuvant therapy for inflammatory...
« Older Entries
Next Entries »

VISIT US

Biocant Park
Núcleo 04, Lote 2
3060-197 Cantanhede
Portugal

CONTACT US

+351 231 419 043 (Call to the national fixed network)

team@exogenus-t.com

jobs@exogenus-t.com

QUICK LINKS

Team
Pipeline
Extracellular Vesicles
Privacy Policy

FOLLOW US

  • FollowFollow
  • FollowFollow
  • FollowFollow